Detalhe da pesquisa
1.
Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
Br J Haematol
; 172(6): 889-901, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26914976
2.
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
Blood
; 120(16): 3260-70, 2012 Oct 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-22932796
3.
The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1.
J Pharmacol Exp Ther
; 346(3): 381-92, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23820125
4.
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Blood
; 118(18): 4771-9, 2011 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-21860026
5.
Probing the effects of DNA-protein interactions on DNA hole transport: the N-terminal histone tails modulate the distribution of oxidative damage and chemical lesions in the nucleosome core particle.
Biochemistry
; 51(14): 3129-42, 2012 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-22409399
6.
Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.
J Biol Chem
; 286(13): 11009-20, 2011 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21189262
7.
Attenuation of DNA charge transport by compaction into a nucleosome core particle.
Nucleic Acids Res
; 34(6): 1836-46, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-16595797
8.
Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients.
Oncotarget
; 9(74): 34009-34021, 2018 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30338042
9.
A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples.
Appl Immunohistochem Mol Morphol
; 24(10): 695-702, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26186254
10.
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
Leukemia
; 34(4): 1197-1201, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31719682
11.
Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.
Clin Cancer Res
; 21(11): 2538-45, 2015 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25748087
12.
Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737.
PLoS One
; 9(9): e103015, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25181509
13.
Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.
Mol Cancer Ther
; 11(10): 2243-53, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22933706
14.
Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo.
Mol Cancer Ther
; 10(1): 148-58, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21062912
15.
Stable DNA-protein cross-links are products of DNA charge transport in a nucleosome core particle.
Biochemistry
; 46(38): 10745-55, 2007 Sep 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-17760420